1. Home
  2. CERO vs PRPO Comparison

CERO vs PRPO Comparison

Compare CERO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • PRPO
  • Stock Information
  • Founded
  • CERO 2017
  • PRPO N/A
  • Country
  • CERO United States
  • PRPO United States
  • Employees
  • CERO N/A
  • PRPO N/A
  • Industry
  • CERO
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • CERO
  • PRPO Industrials
  • Exchange
  • CERO Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • CERO 8.4M
  • PRPO 9.9M
  • IPO Year
  • CERO N/A
  • PRPO N/A
  • Fundamental
  • Price
  • CERO $2.06
  • PRPO $7.22
  • Analyst Decision
  • CERO
  • PRPO
  • Analyst Count
  • CERO 0
  • PRPO 0
  • Target Price
  • CERO N/A
  • PRPO N/A
  • AVG Volume (30 Days)
  • CERO 737.7K
  • PRPO 5.9K
  • Earning Date
  • CERO 02-24-2025
  • PRPO 03-28-2025
  • Dividend Yield
  • CERO N/A
  • PRPO N/A
  • EPS Growth
  • CERO N/A
  • PRPO N/A
  • EPS
  • CERO N/A
  • PRPO N/A
  • Revenue
  • CERO N/A
  • PRPO $17,411,000.00
  • Revenue This Year
  • CERO N/A
  • PRPO $75.18
  • Revenue Next Year
  • CERO N/A
  • PRPO N/A
  • P/E Ratio
  • CERO N/A
  • PRPO N/A
  • Revenue Growth
  • CERO N/A
  • PRPO 31.31
  • 52 Week Low
  • CERO $1.70
  • PRPO $4.31
  • 52 Week High
  • CERO $1,095.00
  • PRPO $7.55
  • Technical
  • Relative Strength Index (RSI)
  • CERO 37.15
  • PRPO 62.56
  • Support Level
  • CERO $1.70
  • PRPO $7.02
  • Resistance Level
  • CERO $2.22
  • PRPO $7.55
  • Average True Range (ATR)
  • CERO 0.30
  • PRPO 0.25
  • MACD
  • CERO 0.27
  • PRPO 0.05
  • Stochastic Oscillator
  • CERO 24.32
  • PRPO 73.78

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: